- Companies
- Ansell
Ansell Valuation Multiples
Ansell is valued at $4.5B as of November 2026, a 2.3x revenue multiple. In the last 12 months, Ansell revenue was $2.2B and Ansell EBITDA was $409M.
Ansell Overview
About Ansell
Ansell is a leading supplier of protective gloves and other wearable PPE for use in healthcare and industrial settings, each contributing about 50% of revenue. Industrial contributes slightly higher EBIT owing to higher margins. The company holds more than 500 patents, and most sales come from its key branded product ranges. Products are sold in about 100 countries, mostly via distributors. Approximately half of revenue is from North America, and about one-third is from Europe, the Middle East, and Asia. Latin America and Asia-Pacific each contribute about 10%.
Founded
1920
HQ
Employees
46.8K
Website
Sectors
Financials (LTM)
EV
$5B
Valuation Multiples
Start free trialAnsell Financials
Ansell reported last 12-month revenue of $2.2B and EBITDA of $409M.
In the same LTM period, Ansell generated $923M in gross profit, $409M in EBITDA, and $215M in net income.
Revenue (LTM)
Ansell P&L
In the most recent fiscal year, Ansell reported revenue of $2.1B and EBITDA of $400M.
Ansell is profitable as of last fiscal year, with gross margin of 41%, EBITDA margin of 19%, and net margin of 10%.
Financial data powered by Morningstar, Inc.
Ansell Stock Performance
Ansell has current market cap of $4.5B, and enterprise value of $5B.
Market Cap Evolution
Ansell's stock price is $31.70.
Ansell share price decreased by 0.7% in the last 30 days, and increased by 29.6% in the last year.
Ansell has an EPS (earnings per share) of $1.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5B | $4.5B | -0.6% | -0.7% | 8.5% | 29.6% | $1.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnsell Valuation Multiples
Ansell trades at 2.3x EV/Revenue multiple, and 12.2x EV/EBITDA.
EV / Revenue (LTM)
Ansell Financial Valuation Multiples
As of November 7, 2026, Ansell has market cap of $4.5B and EV of $5B.
Ansell has a P/E ratio of 20.7x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Ansell Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Ansell Margins & Growth Rates
Ansell grew revenue by 4% and EBITDA by 6% in the last fiscal year.
In the most recent fiscal year, Ansell reported gross margin of 41%, EBITDA margin of 19%, and net margin of 10%.
Ansell Margins
Ansell Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Ansell Operational KPIs
Ansell's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.
Ansell's Rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Ansell's Rule of X is 33% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Ansell Competitors
Ansell competitors include Sotera Health, Cupid, Stevanato Group, Schott Pharma, Shandong Weigao Blood, Haemonetics, Sopharma, Inner Mongolia Furui Medical Science, Dentsply Sirona and Kestra Medical Technologies.
Most Ansell public comparables operate across Medical Supplies.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.2B | $440M | 5.5x | 5.2x | 14.6x | 10.2x | |||
| $37M | $14M | 129.5x | - | 344.4x | - | |||
| $1.3B | $316M | 3.1x | 2.9x | 13.0x | 11.0x | |||
| $1.1B | $313M | 3.4x | 3.2x | 12.0x | 11.8x | |||
| $566M | $123M | 5.5x | 3.7x | 25.1x | 12.9x | |||
| $1.3B | $268M | 4.7x | 4.5x | 23.6x | 15.1x | |||
| $1.5B | $146M | 1.6x | 1.5x | 16.0x | 17.5x | |||
| $239M | $65M | 8.0x | 6.5x | 29.1x | 23.4x | |||
This data is available for Pro users. Sign up to see all Ansell competitors and their valuation data. Start Free Trial | ||||||||
Acquisitions by Ansell
Ansell has acquired 4 companies to date.
Last acquisition by Ansell was on April 8th 2024. Ansell acquired Kimberly-Clark (personal protective equipment unit) for $640M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Ansell
| Description | - | Ringers Gloves is a safety equipment manufacturer specializing in impact-resistant gloves for oil and gas, construction, and industrial workers. Headquartered in Houston, Texas, it engineers padded backhand protection models like Powderhead and Static Line for mechanical hazards. Ringers Gloves distributes worldwide to energy and manufacturing sectors. | Digitcare Corporation is a provider of medical care services focused on podiatry and wound care. Operating clinics in New Jersey, it offers treatments for foot disorders, diabetic care, and surgical procedures. | Nitritex is a manufacturer of cleanroom consumables under the BioClean brand, including gloves, swabs, and wipers for semiconductor and pharmaceutical environments. Based in Hungerford, Berkshire, United Kingdom, the company produces sterile and non-sterile products certified to ISO Class 4 standards, minimizing particle and extractable contamination. Nitritex supplies facilities for OLED display production and bioprocessing in Asia and Europe. |
| HQ Country | ||||
| HQ City | - | Houston, TX | Los Angeles, CA | Newmarket |
| Deal Date | 8 Apr 2024 | 1 Feb 2019 | 31 Oct 2018 | 30 Jan 2017 |
| Valuation | $640M | $70M | undisclosed | $56M |
| EV/Revenue | ||||
| EV/EBITDA | ||||
This data is available for Pro users. Sign up to see all Ansell acquisitions and their M&A valuation multiples. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Ansell
| When was Ansell founded? | Ansell was founded in 1920. |
| Where is Ansell headquartered? | Ansell is headquartered in Australia. |
| How many employees does Ansell have? | As of today, Ansell has over 46K employees. |
| Who is the CEO of Ansell? | Ansell's CEO is Neil I. Salmon. |
| Is Ansell publicly listed? | Yes, Ansell is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Ansell? | Ansell trades under ANN ticker. |
| When did Ansell go public? | Ansell went public in 1985. |
| Who are competitors of Ansell? | Ansell main competitors include Sotera Health, Cupid, Stevanato Group, Schott Pharma, Shandong Weigao Blood, Haemonetics, Sopharma, Inner Mongolia Furui Medical Science, Dentsply Sirona, Kestra Medical Technologies. |
| What is the current market cap of Ansell? | Ansell's current market cap is $4.5B. |
| What is the current revenue of Ansell? | Ansell's last 12 months revenue is $2.2B. |
| What is the current revenue growth of Ansell? | Ansell revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Ansell? | Current revenue multiple of Ansell is 2.3x. |
| What is the current EBITDA of Ansell? | Ansell's last 12 months EBITDA is $409M. |
| What is Ansell's EBITDA margin? | Ansell's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Ansell? | Current EBITDA multiple of Ansell is 12.2x. |
| What is the current FCF of Ansell? | Ansell's last 12 months FCF is $310M. |
| What is Ansell's FCF margin? | Ansell's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Ansell? | Current FCF multiple of Ansell is 16.1x. |
| How many companies Ansell has acquired to date? | As of November 2026, Ansell has acquired 4 companies. |
| In how many companies Ansell has invested to date? | Ansell hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Ansell
Lists including Ansell
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




